The updated Medscheme specialised drug list for 2023 has been published

By HEOR Staff Writer

May 12, 2023

Reimbursement is still dependent on authorisation and benefit limits.

Some drugs included:
ANTIHEMORRHAGICS
Hemlibra

CARDIOVASCULAR SYSTEM
Volibris

DERMATOLOGICALS
Dupixent

ANTIVIRALS FOR SYSTEMIC USE
Epclusa

ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy

IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair

Reference url

Recent Posts

Exploring MFN Policy Effectiveness in Drug Pricing and Innovation

By João L. Carapinha

February 19, 2026

MFN Policy Effectiveness in Countering Freeloading Claims The MFN policy effectiveness is evident in the coalition letter dated February 12, 2026, which opposes codifying Most-Favored-Nation (MFN) prescription drug pricing b...
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implications for Alzheimer&...

By HEOR Staff Writer

February 18, 2026

Dutch Health Insurance Rejects Lecanemab Coverage Zorginstituut Nederland's advisory letter dated 13 February 2026 recommends against including lecanemab (Leqembi®) in the Dutch basic health insurance package, marking a key lecanema...
Revised MenACWY Vaccination Strategy for Adolescents in Germany

By HEOR Staff Writer

G-BA Approves MenACWY Vaccination Strategy Shift for Adolescents Germany's Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) has approved key amendments to the Protective Vaccination Directive on December 18...